# How do software vendors sell to pharma, biotech and medtech companies?

> **The short answer:** Software vendors sell to biopharma and medtech companies through a buying group where QA, IT, security, legal and finance can each veto. By our estimate, groups hold 5–12 people and deals run 6–18 months. Deals open on dated triggers such as a financing round, a Phase 3 start or an FDA 483, and slip when GxP supplier qualification starts late.

- Page: https://panelhop.com/industries/pharma/
- Section: Home › Industries › Pharma and life sciences
- Updated 5 October 2026 · Based on Panelhop research, October 2026
- Written for: Vendors selling to biopharma and medtech companies
- Publisher: Panelhop (https://panelhop.com/)

**Your life sciences deals slip after the verbal yes.** You sell to biopharma and medtech companies, and you can name the accounts worth working. After the verbal yes, QA audits you, security sends its questionnaire and the close date moves. Biotech deals vanish after a failed readout, and the year-end forecast carries unfunded deals.

- GxP supplier qualification and security review: 2–6 months (Illustrative)
- German medtech makers, more than 20 staff: 1,508
- Analysed vendors likely to stall at GxP qualification: 12 of the 13

## Pharma and life sciences · How a deal really moves

**The champion says yes. Then QA audits you. IT, security and finance object after the shortlist.** (Illustrative)

With Panelhop: The same deal, with QA and IT in early. Supplier qualification opens at the first meeting, not the yes.

One pharma or medtech company, 5–12 people and an estimated 6–18 months from first signal to signature.

What opens a deal:

- **Biotech Series B or C closes** (Funding)
- **Phase 3 start or PDUFA date** (Milestone)
- **FDA 483 or warning letter** (Regulation · US)
- **QMSR, EUDAMED and MDR dates** (Deadline · US, EU)
- **Acquisition closes** (Consolidation)
- **New CIO or head of quality** (Leadership)

The buyer: **A pharma or medtech company**. Biotech, pharma, medtech, IVD, CRO or CDMO. 671 pharma · 1,508 medtech makers in Germany.

Who decides:

| Seat | What worries them | Can veto |
|---|---|---|
| Quality or clinical head | A failed validation that turns into an inspection finding. | Yes |
| CFO, CEO and board | Spend that does not move a trial, a filing or a launch. | Yes |
| IT and architecture | Point solutions that add integrations and revalidation. | Yes |
| CSV and supplier quality | Relying on a SOC 2 report an inspector will not accept. | Yes |
| Information security | Ransomware reaching plant or trial data through a supplier. | Yes |
| Legal and DPO | Data leaving the EU, or terms that block inspection support. | Yes |
| Procurement | Price creep through add-ons, seats and renewal uplifts. | No |
| Process owner and users | Migration on top of the day job, and a lost audit trail. | No |

How the deal moves:

| Stage | Typical time | Where it stalls today | With Panelhop | Service |
|---|---|---|---|---|
| Targeting | 2–8 weeks | By the time you call, the systems are chosen | Accounts with a live trigger, scored, in your CRM every week | Signal Desk (In-market accounts, weekly): https://panelhop.com/services#signal |
| Demand generation | – | – | – | – |
| First meeting | – | – | – | – |
| Discovery | 3–8 weeks | – | – | – |
| Evaluation | 1–3 months | The champion loves it. IT and QA veto it | A second function, such as IT or QA, engaged before scripted demos | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Pilot | 2–12 weeks | A low-fee first study, no budget to scale it | No pilot starts without a budget owner, a success test and a date | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Supplier qualification | 2–6 months | QA audits you after the verbal yes | Supplier qualification is a forecast stage, opened at the first meeting | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Commercial close | 1–3 months | – | – | – |
| Go-live | – | – | – | – |
| Expansion | – | One study lands, then the account goes quiet | Expansion triggers and renewal tasks run with your team, every month | Panel Ops (We run it monthly): https://panelhop.com/services#run |

With Panelhop across the deal: Signal Desk · weekly on what opens a deal (in-market accounts, scored and mapped); Panel Check on the buyer (coverage baselined); Panel Ops · monthly from the last stage back to the next trigger (scores and plays tuned against the baseline).

*Source: Stages, seats, triggers and stalls from Panelhop research, October 2026; [BVMed (Bundesverband Medizintechnologie)](https://www.bvmed.de/branche/zahlen-und-fakten); [BPI (Bundesverband der Pharmazeutischen Industrie), citing Destatis structural statistics](https://www.bpi.de/index.php?eID=dumpFile&t=f&f=83922&token=c99adf6283e76399ccac8e4d686453784b2e3a03); the services as described on the Services page.*
*Note: Durations, panel sizes and cycle lengths are Panelhop estimates from our research, not measurements.*

## At a glance

| Fact | Value |
|---|---|
| Deal size | Roughly €10–450k a year, from a start-up’s cloud eQMS to an enterprise platform, mostly converted from US dollar pricing (Illustrative) |
| Sales cycle | 6–18 months for most deals; 1–9 months at clinical-stage biotech (Illustrative) |
| Buying panel | 5–12 people; QA, IT, security, legal and finance can each veto (Illustrative) |
| Supplier qualification | 2–6 months of GxP audit and security review (Illustrative) |
| How deals start | A dated trigger: a financing round, a Phase 3 start, an FDA 483 or a regulatory deadline |
| Segments | Top-tier biopharma, mid-size pharma, clinical-stage biotech, medtech and IVD makers, CROs and CDMOs |

*Source: Panelhop research, October 2026.*
*Note: Values marked Illustrative are Panelhop estimates from our research, not measurements.*

## Why do software deals with pharma and medtech companies stall?

**The system leaks before the market runs dry.**

Software deals with pharma and medtech companies stall when GxP supplier qualification starts after the verbal yes and one champion carries a deal that QA, IT or finance can veto. Flat target lists, funnels that count people instead of accounts, unfunded deals in the forecast and first studies that never spread leak too. None of these leaks is a shortage of accounts.

**Exhibit 1: Where the pipeline leaks: 6 points across 10 stages.**

1. **Reps spend quarters on accounts that cannot buy this year** (stage: Targeting). What you see: Reps spend quarters on the largest pharma groups and on preclinical biotechs while closable mid-market deals wait. Why it happens: No tier model combines segment, clinical phase, funding, installed platform and deadline exposure. In our analysis of life sciences vendors’ websites, none of the 13 vendors segments by clinical phase, installed platform or regulatory deadline.
2. **Your webinars fill with scientists who hold no budget** (stage: Demand generation). What you see: Webinar sign-ups and downloads rise while qualified opportunities stay flat, and pipeline jumps after the June and October congresses. Why it happens: The funnel counts individuals instead of accounts, and engagement is not separated from sales activation. A scientist can like a product months before anyone funds it.
3. **Your champion says yes, then IT or QA says no** (stage: Evaluation). What you see: One named contact sits on the opportunity for months, then IT says ‘another integration’ or QA says ‘we must audit you’. Why it happens: In our analysis of life sciences vendors’ websites, single-threaded deals were a likely bottleneck for 10 of the 13 vendors. Only 3 of the 13 vendor sites address finance at all.
4. **Close dates slip while QA and security review you** (stage: Supplier qualification). What you see: Close dates move while the deal sits ‘in procurement’, and a long security questionnaire lands on an engineer. Why it happens: Supplier qualification is not a stage in the CRM or the forecast. In our analysis of life sciences vendors’ websites, late supplier qualification was a likely bottleneck for 12 of the 13 vendors. No vendor in that sample publishes an audit-ready pack.
5. **Q4 carries deals that need next year’s money** (stage: Commercial close). What you see: Buyers say they like it but have no budget until next year, and biotech deals vanish after a failed readout. Why it happens: Nobody records each account’s budget window, financing or programme news, so the forecast mixes funded and unfunded deals.
6. **You land one study, and the account stops there** (stage: Expansion). What you see: The logo count grows while revenue per account stays flat. Why it happens: Relationships stay inside the landing team and pricing is per study or site. In our analysis of life sciences vendors’ websites, failure to expand beyond the first study, site or brand was a likely bottleneck for 11 of the 13 vendors.

*Source: Panelhop research, October 2026.*

## What are the buying signals at pharma, biotech and medtech companies?

**Dated, public events open life sciences budgets.**

Financing rounds, phase moves, inspection findings, fixed regulatory dates, acquisitions, new leaders and end-of-support notices open life sciences deals. Most of them are public and dated. Acting on a trigger takes a dated field on the account and a named owner who moves the same day.

**Exhibit 2: The 8 events that open or close the window for a deal.** (Illustrative)

- **Biotech financing round** (Funding). What happens: A clinical-stage biotech closes a Series A, B or C round that names a trial start. Where to spot it: Financing trackers, company press releases and the BioIndustry Association’s quarterly UK data. Window: Purchases tend to follow 1–6 months after close, tied to the next study start.
- **Phase move, filing or PDUFA date** (Budget cycle). What happens: A move from Phase 2 to Phase 3, a BLA or NDA filing or a PDUFA date leaves the sponsor needing a validated safety database, submission tools and launch systems. Where to spot it: Authorised trials on the CTIS public portal, company press releases and investor decks. Window: Opens 6–12 months before the milestone.
- **FDA 483 or warning letter** (Regulation). What happens: FDA cites a site, contract lab or CDMO for data integrity failures such as shared logins or unreviewed audit trails, and the cited firm’s customers then review their own suppliers. Where to spot it: FDA’s public warning letter database, scanned each week, plus 483s that FDA publishes or companies disclose, which arrive later. Window: CAPA plans are written within weeks and run for 6–24 months.
- **Device deadlines: QMSR, EUDAMED, MDR and IVDR** (Regulation). What happens: QMSR has applied to device makers since 2 February 2026, and devices already on the EU market that are still being placed on it must be registered in EUDAMED by 28 November 2026. Where to spot it: FDA’s QMSR pages, the European Commission’s EUDAMED pages and each maker’s notified body certificates. Window: Open now; MDR transition periods end on 31 December 2027 or 31 December 2028, IVDR transitions for legacy diagnostics between 31 December 2027 and 31 December 2029, and remediation and certification work runs until then.
- **GMP and GCP rule changes** (Regulation). What happens: Drafts of EU GMP Annex 11, Chapter 4 and a new Annex 22 on AI went to consultation from 7 July to 7 October 2025. Where to spot it: The European Commission’s consultation page, EMA’s ICH E6 page and new questions in buyers’ supplier questionnaires. Window: Gap assessments are running now, but final texts are still awaited and some buyers wait for them; remediation budgets land in 2027, and ICH E6(R3) Annex 2 takes effect in the EU on 15 January 2027.
- **Acquisition closes** (Consolidation). What happens: A pharma, biotech, CRO or CDMO deal closes and integration teams decide which systems to keep, consolidate or replace. Where to spot it: M&A trackers and closing notices in company filings. Window: Planning starts at signing; purchases follow 0–12 months after close, and renewals come under review.
- **New CIO, quality or regulatory leader** (Leadership). What happens: A new technology, quality, regulatory or safety leader reviews the systems and the vendors behind them. Where to spot it: Industry appointment roundups, press releases and job changes at target accounts. Window: Opens 3–9 months after the start date.
- **Platform end of support** (Technology). What happens: Legacy commercial CRMs, on-premises quality systems and older manufacturing software reach end of support, so customers re-platform and compare alternatives. Where to spot it: End-of-support notices, consultancy commentary and migration job postings. Window: Opens 12–36 months before the end-of-support date.

*Source: Panelhop research, October 2026; [US Food and Drug Administration](https://www.fda.gov/medical-devices/quality-management-system-regulation-qmsr/quality-management-system-regulation-frequently-asked-questions); [European Commission, DG SANTE](https://health.ec.europa.eu/document/download/3bb39d28-dcaa-4907-9ea9-ea89cee091c0_en?filename=md_eudamed_tp-leg-reg-devices_en.pdf); [European Medicines Agency](https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline).*
*Note: Timings are Panelhop estimates from our research, not measurements.*

## Who signs off on a software deal at a biopharma or medtech company?

**One budget owner sponsors; most seats can veto.**

The function head who owns the budget sponsors a GxP software deal, and the executive team or board signs. IT, computerised system validation, security, legal and finance can each stop it. By our estimate, the panel runs from 3–5 people at a small biotech or medtech maker to 8–12 or more for an enterprise platform.

**Exhibit 3: At a mid-size pharma or established medtech company buying a GxP system, 5–12 people sit on the panel and 6 seats can stop the deal.** (Illustrative)

At a mid-size pharma or established medtech company buying a GxP system: 5–12 people.

| Seat | Typical titles | Cares about | Worries about | Can veto |
|---|---|---|---|---|
| Function head and budget owner | Chief Quality Officer, VP Clinical Operations, Head of Regulatory Affairs | Inspection readiness, fixed regulatory dates and a business case leadership will sign. | A failed implementation or validation that turns into an inspection finding. | Yes |
| Process owner and lead users | QA Manager, Clinical Data Manager, PV Operations Lead | Fit with real workflows and fewer manual steps for sites, labs and plant staff. | Migration work on top of the day job, and lost data or audit trail. | No |
| IT and enterprise architecture | Chief Information and Digital Officer, Enterprise Architect, IT Business Partner GxP Systems | Fit with the clinical, quality, ERP and CRM platforms already in place. | Point solutions that add integrations and revalidation. | Yes |
| Computerised system validation and supplier quality | CSV Lead, Supplier Quality Auditor, Qualified Person | Part 11 and Annex 11 evidence, the supplier audit outcome and the quality agreement. | Relying on a SOC 2 report that an inspector will not accept as a supplier assessment. | Yes |
| Information security | CISO, IT Security Risk Manager, Third-Party Risk Analyst | SOC 2 Type II and ISO 27001 evidence, and NIS2 duties for the supply chain. | Ransomware that reaches production or trial data through a supplier. | Yes |
| Procurement and vendor management | Category Manager R&D/IT Procurement, Director Vendor Management, Strategic Sourcing Lead | Preferred-vendor lists, price benchmarks and multi-year terms. | Price creep through add-ons, seats and renewal uplifts. | No |
| Legal and data protection | Legal Counsel, Data Protection Officer, Compliance Officer | The DPA, audit rights, change notification, exit and data export clauses. | Data transfers outside the EU and contracts that block inspection support. | Yes |
| Finance, executive team and board | CFO, CEO, Board of Directors | Total cost with validation included, and fit with the funding runway at a biotech. | Spend that does not move a trial, a filing or a launch. | Yes |

*Source: Panelhop research, October 2026.*
*Note: The panel size is a Panelhop estimate from our research, not a measurement.*

## Which pharma, biotech and medtech companies buy software?

**Each segment buys on its own clock.**

Top-tier biopharma, mid-size pharma, clinical-stage biotech, medtech and IVD makers, CROs and CDMOs all buy software, from the largest global groups to single-product start-ups. The accounts worth a rep’s time can be listed by name. Each segment buys on its own cycle and budget, so give each one an account tier before a rep works it.

**Exhibit 4: Medtech and IVD manufacturers in the US are the largest group we could count: over 6,500 medtech companies.** (Illustrative)

| Segment | What they are | Region | Accounts |
|---|---|---|---|
| Top-tier global biopharma | The largest research-based groups buy enterprise platforms through central IT, procurement and QA validation, over 6–24 months by our estimate. The tier also holds large commercial-stage biotechs: the biotech sector had a record 72 companies with more than $500M in sales in 2025. | – | No sourced count |
| Mid-size, specialty and generic pharma | Commercial-stage manufacturers, many of them family-owned Mittelstand firms, buy QMS, LIMS, MES, RIM and safety through site QA and operations rather than global IT. Over 84% of German pharmaceutical manufacturers are micro, small or medium-sized. | DACH | 671 pharmaceutical companies in Germany |
| Emerging and clinical-stage biotech | Venture-funded developers, mostly pre-revenue, buy EDC, eCOA, RTSM, early QMS, RIM and safety, often through a CRO, and spend follows financing rounds and trial starts. Switzerland has 334 biotech companies active in R&D. | DACH | 798 dedicated biotech companies in Germany, across all fields |
| Medtech and IVD manufacturers | Device and diagnostics makers buy eQMS, PLM, UDI and regulatory tools and post-market surveillance, timed by QMSR, EUDAMED, MDR and IVDR dates. Of Europe’s 36,000 medtech companies, 90% are SMEs, and many small makers buy below an account-based deal size. | DACH | 1,508 in Germany with more than 20 staff |
| Medtech and IVD manufacturers | Device and diagnostics makers buy eQMS, PLM, UDI and regulatory tools and post-market surveillance, timed by QMSR, EUDAMED, MDR and IVDR dates. Of Europe’s 36,000 medtech companies, 90% are SMEs, and many small makers buy below an account-based deal size. | US | over 6,500 medtech companies |
| Medtech and IVD manufacturers | Device and diagnostics makers buy eQMS, PLM, UDI and regulatory tools and post-market surveillance, timed by QMSR, EUDAMED, MDR and IVDR dates. Of Europe’s 36,000 medtech companies, 90% are SMEs, and many small makers buy below an account-based deal size. | UK | 59% of 7,600 life sciences companies are medtech |
| CROs and CDMOs | Contract research and manufacturing organisations buy CTMS, EDC, RTSM, safety, LIMS, MES and QMS for their own work, and steer which tools small sponsors use. The EU’s CTIS listed 6,116 ongoing trials at the end of 2025, each needing trial systems that a sponsor or its CRO chose. | – | No sourced count |

*Source: Panelhop research, October 2026; [BPI (Bundesverband der Pharmazeutischen Industrie), citing Destatis structural statistics](https://www.bpi.de/index.php?eID=dumpFile&t=f&f=83922&token=c99adf6283e76399ccac8e4d686453784b2e3a03); [biotechnologie.de / BIOCOM](https://biotechnologie.de/wp-content/uploads/2025/03/BTKB_2024_Statistik.pdf); [BVMed (Bundesverband Medizintechnologie)](https://www.bvmed.de/branche/zahlen-und-fakten); [AdvaMed](https://www.advamed.org/medical-device-industry-facts/); [Office for Life Sciences, GOV.UK](https://www.gov.uk/government/statistics/bioscience-and-health-technology-sector-statistics-2024-to-2025/bioscience-and-health-technology-sector-statistics-2024-to-2025); [MedTech Europe](https://www.medtecheurope.org/about-the-industry/facts-figures/); [scienceindustries](https://www.scienceindustries.ch/en/article/51117/swiss-biotech-report-2026-new-records-in-revenues-and-investments); [EY](https://www.ey.com/en_us/life-sciences/biotech-outlook); [ACT EU (European Commission, EMA and HMA)](https://accelerating-clinical-trials.europa.eu/document/download/1f80fd01-328f-4dd8-8ab6-04c91c466cd2_en?filename=ACT%20EU%20KPI%20Report_December_2025.docx.pdf).*
*Note: Illustrative figures here are Panelhop estimates from our research, not measurements.*

## What do biopharma and medtech buyers ask vendors during a deal?

**Buyers ask about audits, validation and total cost.**

Biopharma and medtech buyers ask whether you will pass their supplier audit, whether you add another validation and what the system costs all in. These questions come from our research into how the market buys, phrased the way buyers raise them.

**Head of QA or CSV lead**

- “Your SOC 2 report is not enough. When can we audit you as a GxP supplier?”
- “How do your releases and change control protect our validated state?”
- “Can we validate your AI features when the draft Annex 22 limits AI in critical GMP use to static, deterministic models?”

**CIO or enterprise architect**

- “We have standardised on a platform. Why add another integration and another validation?”
- “Do you connect to our clinical, quality and CRM platforms without custom work?”

**CFO or procurement**

- “What does it cost all in, with validation, migration and renewal uplifts?”
- “You are a small vendor. What happens to our GxP data if you fail or are acquired?”

**CISO or data protection officer**

- “Is your security evidence mapped to NIS2 Article 21 and the draft Annex 11 security chapter?”
- “Where is our data hosted, and are any owners or subprocessors linked to countries of concern?”

## What are the stages of a software sale to a pharma or medtech company?

**Most life sciences deals stall when someone arrives late.**

A life sciences software deal moves from a dated trigger through requirements, scripted demos and GxP supplier qualification to contract and validation. By our estimate, small medtech makers decide in 1–4 months and clinical-stage biotechs in 1–9 months, while enterprise platforms at top-tier biopharma take 6–24 months. Durations show the buyer’s side, and stages overlap, so they add up to more than the cycle.

**Exhibit 5: Stage by stage: what you do, what the biopharma or medtech company does, and what changes at the 5 stages where deals stall.** (Illustrative)

| Stage | Typical time | What you do | What the biopharma or medtech company does | Today | With Panelhop | Service |
|---|---|---|---|---|---|---|
| Targeting | 2–8 weeks | Works lists sorted by company type, therapy area or function. | A deadline, inspection finding, financing round or new leader creates the need; the function head writes a risk or ROI brief and secures budget. | Accounts are found once the trial is registered or the RFI is out. Stalls: Arriving after the decision. Funding and leadership signals fire months before registration, which in the US can come up to 21 days after the first participant enrols, once the CRO and systems are chosen. | Each week, accounts with a live trigger, such as a financing round, a phase move or an FDA warning letter, arrive in your CRM, scored, with the signal that fired. | Signal Desk (In-market accounts, weekly): https://panelhop.com/services#signal |
| Demand generation | – | Runs webinars, gated content and a stand at a few congresses, then waits for a demo request. | Researches at DIA, RAPS, SCDM, CPHI and The MedTech Conference, in peer networks and in consultants’ evaluation kits before contacting vendors. | Webinars and congresses count sign-ups, one person at a time. | Engagement, including congress attendance, rolls up to the account and its buying group, and only fit, engaged accounts reach a rep, with the reasons on the task. | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| First meeting | – | Meets whoever filled in the form, most often a process owner or lead user. | A QA, clinical data or regulatory operations manager asks for a hands-on demo. | Reps meet whoever filled in the form. | Each account comes with a research brief and its buying group mapped, drafted by AI and reviewed before it reaches your rep. Your reps own the first touch. | Signal Desk (In-market accounts, weekly): https://panelhop.com/services#signal |
| Discovery | 3–8 weeks | Quotes only after a sales call: in our analysis of their websites, 12 of the 13 life sciences vendors show no price or quote only on request. | Writes a URS and sends RFIs; procurement asks whether you already hold an MSA and quality agreement. | One process owner writes the URS with you. | A role map per tier covers IT, CSV, security, procurement and finance on every account, with missing roles enriched and coverage tracked as the deal moves. | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Evaluation | 1–3 months, then 2–6 weeks of references | Runs scripted demos and lines up references from a customer ‘like us’. | Scores demos on a matrix, calls peers and checks fit with the platform estate. | Late vetoes end strong evaluations as no decision. Stalls: One champion, many vetoes. The deal rests on a scientific, quality or commercial champion, and objections from IT, QA, security or finance arrive after the shortlist. | Stage exit criteria require a second function, such as IT or QA, to be engaged before scripted demos. | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Pilot | 2–12 weeks where a pilot runs | Offers a sandbox, a first study or a first site, often at low or no fee. | Lead users and IT test fit; at large pharma an innovation or IT team often funds the pilot. | Pilots start with no budget owner or success test. Stalls: A pilot with no budget owner. The pilot proves feasibility but has no success criteria, validation plan or line-of-business budget for scale, so it is extended or re-tendered. | A mutual action plan names the budget owner, the success test and the decision date before a pilot starts. | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Supplier qualification | 2–6 months | Answers the supplier questionnaire and a security review, often for the first time on this deal. | QA runs a risk-based GxP supplier assessment or audit; security reviews SOC 2 Type II and ISO 27001 evidence. | QA and security first see you after the verbal yes. Stalls: Qualification after the verbal yes. QA’s audit, security’s questionnaire and any CAPA on audit findings start once the champion has chosen, so the close date slips. | Supplier qualification becomes a forecast stage with exit criteria, opened at the first meeting, and its days are tracked on every deal. Your quality team owns the evidence. | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Commercial close | 1–3 months, then 1–4 weeks for sign-off | Negotiates licences, services and the validation package, then waits for signature. | Procurement, legal, QA and finance agree the MSA, DPA and quality agreement; the executive team or board signs. | Funded and unfunded deals share one forecast. | A deal risk score and forecast tracking flag deals without a funded budget line before the forecast call. | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Go-live | – | Configures, migrates data and supports IQ/OQ/PQ. | Validates and releases the system for GxP use with a signed validation summary report. | What sales promised about validation lives in one rep’s head. | A handoff document built from the deal records what was promised about migration, validation and go-live. | Leak Fix (We build the fixes): https://panelhop.com/services#build |
| Expansion | – | Waits for the next study, site, brand or function to ask. | Each therapeutic area, site or function buys on its own; procurement reviews every module at renewal. | Expansion waits for the next team to call. Stalls: One study, site or brand, then silence. Relationships sit inside the team that bought first, and pricing per study or site gives no route to the rest of the company. | Panel Ops operates the expansion triggers and renewal tasks with your team, re-tiers accounts each quarter and reports against the baseline every month. | Panel Ops (We run it monthly): https://panelhop.com/services#run |

*Source: Panelhop research, October 2026; [Electronic Code of Federal Regulations (eCFR), US Office of the Federal Register](https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-11/subpart-B/section-11.24).*
*Note: Typical times are Panelhop estimates from our research, not measurements.*

## How does Panelhop change the way a life sciences deal moves?

**Every stage gets a baseline before anything changes.**

Panelhop maps the whole buying panel and makes supplier qualification a tracked stage from the first meeting of a life sciences deal. A Panel Check (GTM audit) baselines your pipeline metrics in your own CRM data. Signal Desk (in-market accounts, weekly), Leak Fix (we build the fixes) and Panel Ops (we run it monthly) then work the stages that leak, each with a fixed scope and no promised result.

What we baseline and report:

1. Buying-group coverage: contacts engaged per open deal, by role, against the baseline
2. Days from a dated trigger to your rep’s first touch, against the baseline
3. Days each deal spends in supplier qualification, against the baseline

## Which vendor types sell to biopharma and medtech companies?

**Read the pipeline for your vendor type.**

These are the vendor types we map in pharma and life sciences, each with its own buying panel, pipeline and triggers.

- [eClinical software](https://panelhop.com/industries/pharma/eclinical-platforms): EDC, eCOA, eConsent, RTSM, CTMS and eTMF platforms sold to trial sponsors and CROs, priced per study, user or portfolio.
- [eQMS and quality management software](https://panelhop.com/industries/pharma/eqms-quality-management): Cloud eQMS for document control, training, CAPA, audits and supplier quality, sold to device makers, biotechs, pharma sites and CDMOs.
- [Regulatory information and pharmacovigilance software](https://panelhop.com/industries/pharma/regulatory-safety-software): RIM, submission, UDI and safety database software sold to regulatory affairs and drug safety teams at biopharma and medtech companies.
- [Lab and manufacturing software](https://panelhop.com/industries/pharma/lab-manufacturing-software): LIMS, ELN, MES and electronic batch record software sold to QC labs, manufacturing sites and CDMOs in pharma, biotech and medtech.
- [Commercial data and HCP intelligence](https://panelhop.com/industries/pharma/commercial-data-hcp-intelligence): HCP, site, patient and access data and analytics for biopharma commercial, medical affairs, market access and patient services teams.

## What do terms like “GxP” and “URS” mean in pharma and life sciences?

**The words your buyers use, defined.**

Plain definitions of the terms that come up when you sell to biopharma and medtech companies.

- **GxP**: The good practice rules for regulated life sciences work: manufacturing (GMP), clinical trials (GCP), laboratories (GLP) and drug safety. Software that holds GxP records must be validated.
- **URS**: User requirements specification: the buyer’s written list of what a GxP system must do, including hosting and integration needs. It goes out with the RFI and is later traced to validation testing.
- **GxP supplier qualification**: A buyer’s risk-based check of a vendor before it may supply a GxP system: a questionnaire, document review and often a remote or on-site audit, recorded on the approved supplier list.
- **21 CFR Part 11 and EU GMP Annex 11**: 21 CFR Part 11 sets US rules for electronic records and signatures, and EU GMP Annex 11 sets EU rules for computerised systems in GMP manufacturing. QA wants evidence against both before qualifying a vendor.
- **Quality agreement**: A contract separate from the commercial terms that sets audit rights, change and incident notification, release testing, inspection support and exit between a GxP buyer and its supplier.
- **Computerised system validation (CSV)**: Documented, risk-based evidence that a system works as intended in GxP use, often a validation plan, IQ/OQ/PQ testing and a traceability matrix, signed off by the buyer’s QA team.
- **FDA 483 and warning letter**: An FDA 483 lists an investigator’s observations after a site inspection. A warning letter can follow when problems are serious or the response falls short, and both often release remediation budget.
- **Sponsor**: The company that starts, funds and is responsible for a clinical trial. Many biotech sponsors outsource the work, and often the trial systems, to a CRO.
- **CRO and CDMO**: A contract research organisation runs clinical or preclinical studies for sponsors. A contract development and manufacturing organisation develops and makes products for them.
- **CTIS**: The EU’s Clinical Trials Information System, through which sponsors apply for and run trials under the Clinical Trials Regulation. Its public portal shows trials by sponsor, phase and country.

## What do vendors ask about selling to biopharma and medtech companies?

**Answers before your next biopharma or medtech company deal.**

### How long does it take to sell software to a pharma or biotech company?

Selling software to a biopharma or medtech company typically takes 6–18 months, by our estimate, and the segment matters more than the product. Clinical-stage biotechs decide in an estimated 1–9 months, established medtech makers and CROs in 3–12 months and mid-size pharma in 4–18 months. Enterprise platforms at top-tier biopharma take an estimated 6–24 months, and GxP supplier qualification can add an estimated 2–6 months.

### Who is in the buying group when a biopharma company buys GxP software?

The buying group for GxP software at a biopharma or medtech company is led by the function head who owns the budget, often in quality, clinical operations, regulatory or safety. IT, computerised system validation, information security, legal and finance can each veto. Process owners shape the choice, and validation consultants or CROs often influence the shortlist. By our estimate, the group has 5–12 people, or 3–5 people at a small biotech or medtech firm.

### How does a software vendor get on a big pharma preferred vendor list?

A software vendor gets on a big pharma preferred vendor list by signing an MSA and a quality agreement before a project needs them. It also has to pass GxP supplier qualification, which a SOC 2 report does not replace, to join the approved supplier list. Large biopharma companies are consolidating suppliers and tend to give new work to vendors already approved. Build a relationship with category management early, and pick a niche, such as a therapy area, modality or region, where a specialist can win.

### How long does GxP supplier qualification take for a software vendor?

GxP supplier qualification of a software vendor at a biopharma or medtech company takes an estimated 2–6 months. QA runs a risk-based supplier assessment, often with a remote or on-site audit, while security reviews SOC 2 Type II and ISO 27001 evidence. A SOC 2 report does not replace the audit. Opening qualification at the first meeting lets it run alongside the evaluation instead of after the verbal yes.

### What are the buying signals for selling to biotech companies?

The strongest buying signals at biotech companies are a financing round that names a trial start and a move from Phase 2 to Phase 3. A filing or PDUFA date, an acquisition and a new clinical, quality or regulatory leader open windows too. Trial registration is a late signal: US rules allow up to 21 days after the first participant enrols, by which time the CRO and systems are chosen. Record each signal as a dated field on the account.

### When do pharma and medtech companies set their budgets?

Larger pharma and medtech companies tend to set next year’s IT and quality budgets in Q3 and Q4, by our estimate. Pharma brand plans run from late spring to autumn, while biotech budgets follow financing rounds and trial starts. A need found late in the year without a funded line usually waits for the next cycle. Record each account’s budget window on the opportunity.

### Why do life sciences webinars and downloads not turn into pipeline?

Life sciences webinars and downloads often reach scientists, students and academics who hold no budget, and interest arrives months before money does. Counting individuals hides which biopharma and medtech accounts are engaged. Qualify accounts instead: fit with your closed-won customers plus engagement from more than one role in the buying group, such as quality and IT together. Then separate engagement metrics from sales activation in your CRM.

### How do software vendors multi-thread deals at pharma and medtech companies?

Software vendors multi-thread biopharma and medtech deals by mapping every seat that can veto at the first meeting. Those seats are usually QA, IT, computerised system validation, security, legal and finance. They open GxP supplier qualification at the same time and give each role the evidence it asks for. They then track the roles engaged on each open deal against a baseline, so gaps show before the shortlist forms.

## Sources

**Where the numbers come from.**

Sourced figures link to their source below. Figures marked Illustrative, and figures given as estimates, are inferred from Panelhop research. Vendors appear only as types, never by name.

1. [BVMed (Bundesverband Medizintechnologie), Zahlen und Fakten (2025)](https://www.bvmed.de/branche/zahlen-und-fakten)
2. [MedTech Europe, Facts & Figures: About the industry (2026)](https://www.medtecheurope.org/about-the-industry/facts-figures/)
3. [AdvaMed, Medical Device Industry Facts (2026)](https://www.advamed.org/medical-device-industry-facts/)
4. [Office for Life Sciences, GOV.UK, Bioscience and health technology sector statistics 2024 to 2025 (2026)](https://www.gov.uk/government/statistics/bioscience-and-health-technology-sector-statistics-2024-to-2025/bioscience-and-health-technology-sector-statistics-2024-to-2025)
5. [BPI (Bundesverband der Pharmazeutischen Industrie), citing Destatis structural statistics, Pharma-Daten 2025 (2026)](https://www.bpi.de/index.php?eID=dumpFile&t=f&f=83922&token=c99adf6283e76399ccac8e4d686453784b2e3a03)
6. [biotechnologie.de / BIOCOM, Die deutsche Biotechnologie-Branche 2024: Daten und Fakten (2025)](https://biotechnologie.de/wp-content/uploads/2025/03/BTKB_2024_Statistik.pdf)
7. [scienceindustries, Swiss Biotech Report 2026: new records in revenues and investments (2026)](https://www.scienceindustries.ch/en/article/51117/swiss-biotech-report-2026-new-records-in-revenues-and-investments)
8. [ACT EU (European Commission, EMA and HMA), Monitoring the European clinical trials environment, October–December 2025 (2026)](https://accelerating-clinical-trials.europa.eu/document/download/1f80fd01-328f-4dd8-8ab6-04c91c466cd2_en?filename=ACT%20EU%20KPI%20Report_December_2025.docx.pdf)
9. [Electronic Code of Federal Regulations (eCFR), US Office of the Federal Register, 42 CFR § 11.24: When must clinical trial registration information be submitted? (2026)](https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-11/subpart-B/section-11.24)
10. [US Food and Drug Administration, Quality Management System Regulation: Frequently Asked Questions (2026)](https://www.fda.gov/medical-devices/quality-management-system-regulation-qmsr/quality-management-system-regulation-frequently-asked-questions)
11. [European Commission, DG SANTE, EUDAMED transition period: legacy and Regulation devices placed on the market before the mandatory use (2026)](https://health.ec.europa.eu/document/download/3bb39d28-dcaa-4907-9ea9-ea89cee091c0_en?filename=md_eudamed_tp-leg-reg-devices_en.pdf)
12. [European Commission, DG SANTE, Extension of the MDR transitional period and removal of the sell-off periods: questions and answers (2024)](https://health.ec.europa.eu/document/download/592008f6-3456-4afb-a13a-733a87da1b00_en?filename=mdr_proposal_extension-q-n-a.pdf)
13. [European Commission, DG SANTE, Stakeholders’ consultation on EudraLex Volume 4, Good Manufacturing Practice guidelines: Chapter 4, Annex 11 and new Annex 22 (2025)](https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-4-good-manufacturing-practice-guidelines-chapter-4-annex_en)
14. [European Medicines Agency, ICH E6 Good clinical practice: scientific guideline (2026)](https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline)
15. [BioIndustry Association, UK biotech venture investment reaches five-year high in Q2 2026, driven by record private financing (2026)](https://www.bioindustry.org/resource/uk-biotech-venture-investment-reaches-five-year-high-in-q2-2026-driven-by-record-private-financing.html)
16. [EY, Biotech Beyond Borders Report 2026 (2026)](https://www.ey.com/en_us/life-sciences/biotech-outlook)
17. [European Commission, DG SANTE, Extension of the IVDR transitional periods: Q&A on practical aspects of the extended transitional period (2024)](https://health.ec.europa.eu/document/download/dfd7a1c6-f319-4682-9bac-77bef1165818_en)
18. [Electronic Code of Federal Regulations (eCFR), US Office of the Federal Register, 21 CFR Part 11: Electronic records; electronic signatures (2026)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11)
- Panelhop research, October 2026: our analysis of the vendors, buying panels, pipelines and triggers in pharma and life sciences, from public sources. Vendor names are not published.

## Next step

Find where your pipeline to biopharma and medtech companies leaks.

[Book a GTM audit](https://panelhop.com/book) · [What the Panel Check covers](https://panelhop.com/services#audit)